GGrantIndex
← Leaderboards

Jef Karel De Brabander

University Of Texas Sw Med Ctr/Dallas

$8,898,818
Attributed
$10,769,442
Total exposure
11
Grants
8
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.5M · FY200521
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21

Funding mix

By agency

NIH$10,769,442 · 11

By mechanism

R01$5,312,910 · 3
P01$3,899,799 · 1
RC1$949,060 · 1
R56$567,000 · 1
P30$32,164 · 1
P41$8,509 · 4

Top collaborators

Most similar at University Of Texas Sw Med Ctr/Dallas

Same institution · by research overlap

Others in their field

Top investigators on “Biological

Research focus

BiologicalBaseComplexStructurePharmaceutical PreparationsProgramsSynthesis ChemistryLeadCellsAnalogScaffoldHigh Throughput ScreeningAreaLaboratoriesBiological FactorsFuturePropertyMarinesMolecularInterestSignal PathwayIn VivoExhibitsMalignant Neoplasms

Grant awards (31)

Structural elucidation and development of agonists for the human orexin receptors$556,297
R01 · FY2021 · NS
Structural elucidation and development of agonists for the human orexin receptors$556,297
R01 · FY2020 · NS
Chemistry and Cancer Scientific Program$32,164
P30 · FY2020 · CA · contact PI
Structural elucidation and development of agonists for the human orexin receptors$556,297
R01 · FY2019 · NS
Structural elucidation and development of agonists for the human orexin receptors$556,297
R01 · FY2018 · NS
Structural elucidation and development of agonists for the human orexin receptors$567,000
R56 · FY2017 · NS
Structural elucidation and development of agonists for the human orexin receptors$1
R01 · FY2017 · NS
Chemical and Biological Optimization of a Gram negative Selective Antibiotic$239,584
R01 · FY2016 · GM · contact PI
Chemical and Biological Optimization of a Gram negative Selective Antibiotic$238,861
R01 · FY2015 · GM · contact PI
Identifying the Molecular Targets of Novel Cytotoxic Agents$784,750
P01 · FY2011 · CA · contact PI
Identifying the Molecular Targets of Novel Cytotoxic Agents$809,475
P01 · FY2010 · CA · contact PI
Development of Small Molecule Orexin Receptor Agonists for Treating Narcolepsy$487,799
RC1 · FY2010 · NS · contact PI
Chemistry and Biology of Antitumor Natural Products$252,482
R01 · FY2010 · CA · contact PI
Identifying the Molecular Targets of Novel Cytotoxic Agents$795,074
P01 · FY2009 · CA · contact PI
Development of Small Molecule Orexin Receptor Agonists for Treating Narcolepsy$461,261
RC1 · FY2009 · NS · contact PI
Chemistry and Biology of Antitumor Natural Products$252,482
R01 · FY2009 · CA · contact PI
Identifying the Molecular Targets of Novel Cytotoxic Agents$656,080
P01 · FY2008 · CA · contact PI
Chemistry and Biology of Antitumor Natural Products$252,482
R01 · FY2008 · CA · contact PI
SYNTHESIS OF MARINE DERIVED MACROCYCLIC SALICYLATES$318
P41 · FY2008 · RR · contact PI
Identifying the Molecular Targets of Novel Cytotoxic Agents$854,420
P01 · FY2007 · CA · contact PI
Chemistry and Biology of Antitumor Natural Products$252,482
R01 · FY2007 · CA · contact PI
SYNTHESIS OF MARINE DERIVED MACROCYCLIC SALICYLATES$565
P41 · FY2007 · RR · contact PI
Chemistry and Biology of Antitumor Natural Products$260,023
R01 · FY2006 · CA · contact PI
SYNTHESIS OF MARINE DERIVED MACROCYCLIC SALICYLATES$554
P41 · FY2006 · RR · contact PI
Chemistry and Biology of Salicylate Natural Products$263,640
R01 · FY2005 · CA
SYNTHESIS OF MARINE DERIVED MACROCYCLIC SALICYLATES$4,504
P41 · FY2005 · RR
Chemistry and Biology of Salicylate Natural Products$263,640
R01 · FY2004 · CA
SYNTHESIS OF MARINE DERIVED MACROCYCLIC SALICYLATES$2,568
P41 · FY2004 · RR
Chemistry and Biology of Salicylate Natural Products$263,640
R01 · FY2003 · CA
Chemistry and Biology of Salicylate Natural Products$263,640
R01 · FY2002 · CA
Chemistry and Biology of Salicylate Natural Products$284,765
R01 · FY2001 · CA